Biotech Values

[DragonBits]

tinkershaw, not sure what TEVA gains by keeping the shareprice up. Insiders selling is one thing, but they often get stock so cheap they don't care so much at what price they sell, a secardary offering is a more common reason to want a higher share price, but other than that a higher or lower share price doesn't help a company. At least not as long as the share price is above 5.00 or market cap is high enough for instutional investors.

The negative is pissing off the FDA and some loss in creditability.

I suppose time will tell, but from what I can gather, TEVA will never get a rejection of lovenox, so that issue may never become clear.

I guess the only good side to this is that MNTA keeps getting more valuable as the share price stays about the same. Less downside.